Baxter BioPharma Solutions

Sterile Parenteral Contract Manufacturing

Support services for parenteral products

BioPharma Solutions partners with pharmaceutical companies to support their commercialization objectives by providing the scientific expertise, sterile contract manufacturing solutions, parenteral delivery systems, and customized support services needed to meet unique challenges that parenteral products face.

The company offers:

  • Commitment to partnering
  • Diverse experience with a variety of drug categories and parenteral delivery systems
  • Scientific and manufacturing expertise, including our Lyophilisation Center of Excellence
  • Worldwide sterile manufacturing capabilities
  • Customized support services, including formulation development and sales and marketing capabilities
  • Experience with worldwide regulatory agencies
  • Quality systems

Award-winning sterile current good manufacturing practice (cGMP) manufacturing with a global presence

With more than 50 manufacturing facilities across six continents, Baxter's global presence provides opportunities for unique manufacturing collaborations to offer the most value for our partners. The power of an extensive global network lies in the coordination of, and efficiencies resulting from, a systemic approach to cGMP manufacturing.

Recent industry achievements:

  • 2016 Facility of the Year (FOYA) category award for Operational Excellence
  • 2016, 2015, 2013, 2012: CMO Leadership Awards (multiple categories), Life Science Leader Magazine
  • 2015, 2012-2010: Best Contract Manufacturing Organization at the Vaccine Industry Excellence Awards
  • 2012 Safebridge Certification: BioPharma Solutions' Halle and Bielefeld facilities in Germany are certified by SafeBridge for both parenteral drug substance synthesis and parenteral drug product manufacturing and testing
  • 2009: Most Effective Scale-Up / Technical Transfer for Managing a Fast-Track Project in a cGMP Environment at theEuropean Outsourcing Awards

Syringe, cartridge and vial filling, delivery systems and drug categories

As a parenterals specialist with over 80 years of expertise, Baxter BioPharma Solutions offers unique drug delivery systems and a variety of contract manufacturing form / fill / finish services and solutions for injectables, which are designed to meet complex and traditional sterile manufacturing challenges. BioPharma Solutions provides its clients with confidence of delivery, service and integrity - we know the work we do is ultimately vital to the patients you serve. Areas of expertise include:

Sterile contract manufacturing solutions:

  • Prefilled syringe filling
  • Liquid vial filling
  • Lyophilized vial filling
  • Cartridge filling
  • Diluents for reconstitution
  • Ampoule filling
  • Powder filled vials
  • Sterile crystallization

Parenteral delivery systems:

  • Frozen premix system
  • Liquid premix system
  • Bio-set luer system

Drug categories:

  • Small molecules
  • Biologics (monoclonal antibodies, therapeutic proteins)
  • Vaccines (adjuvant, conjugate)
  • Cytotoxics
  • Antibody-drug conjugates (ADC)
  • Highly potent compounds

Proprietary parenteral delivery systems

Baxter's heritage is built on over 80 years of innovation in healthcare, including a long list of firsts. As with the first manufacturer-prepared intravenous (IV) solutions, Baxter continues to make history with life-saving and sustaining products.

Baxter's Frozen and Liquid Premix systems and BIO-SET Luer system provide a unique menu of packaging options to meet critical patient needs while growing your product's market advantage. Whether your product is new to market or firmly established, Baxter's portfolio of parenteral delivery systems can create advantages even in crowded drug classes - and build long-lasting market differentiation.

Baxter offers:

  • A history of innovation as the first company to introduce premixed drugs in IV containers and to form alliances with pharmaceutical companies to package their drugs in IV containers
  • Proven expertise with more than one billion sterile units manufactured per year
  • An established clinician user base, providing a valuable distribution channel to help expedite new product introductions, along with sales and marketing support services
  • Global reach with marketing and manufacturing resources
  • Full-service capabilities from development work through commercialization

Contact Details

Baxter Healthcare Corporation
BioPharma Solutions
One Baxter Parkway
Deerfield, IL 60015
United States of America
Contact: Laura Salo
+1 800 4 Baxter
Cytotoxic Manufacturing and Highly Potent Compound Manufacturing
Cartridge Fill Finish
Liquid Vial Fill Finish
Lyophilized Vial Fill Finish
Prefilled Syringe Fill Finish

Available White Papers


Best Practices in Formulation and Lyophilization Development: Proteins, monoclonal Antibodies (mAb), and Antibody Drug Conjugates (ADC) 07 February 2017 The ultimate goal of formulation development is a stable product. In the case of a protein product, that can be defined as delivering the correct dose, in the native secondary and tertiary structure, without unintended chemical modifications and free of extrinsic and intrinsic particles.


Pharmaceutical Development for ADCs 09 February 2015 Formulation, process and analytical development for antibody-drug conjugates (ADCs) can be complex.


A Clinical Perspective on IV Medication Delivery 09 February 2015 Management of medication delivery through intravenous (IV) administration is a complex and challenging task for pharmacists.


The Scientific Path to Cycle Development: Optimizing the Lyophilization Process 26 March 2014 Management of medication delivery through lyophilization, freeze-drying, is a crucial enabling process technology for many important parenteral drugs.